Workflow
美股异动丨Arvinas盘前涨近4% 与辉瑞将vepdegestrant的商业化权利对外转授权
Ge Long Hui·2025-09-18 09:36

Group 1 - Arvinas and Pfizer have decided to sublicense the commercialization rights of the innovative drug vepdegestrant, which is an investigational estrogen receptor degrader for breast cancer [1] - The FDA approval application for vepdegestrant was submitted in June [1] - Following significant changes in the vepdegestrant project, Arvinas plans to lay off 15% of its workforce to seek greater strategic business development opportunities and identify more efficiency improvement areas [1] Group 2 - Arvinas' pre-market stock price increased by 3.81% to $7.90, while Pfizer's pre-market stock price rose by 0.75% [1] - As of the last trading session, Arvinas closed at $7.61 with a market capitalization of $559 million [1] - The stock has a 52-week high of $29.61 and a low of $5.90, indicating significant volatility [1]